Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 3, 2019
UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today ...
January 3, 2019
ProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR) will host a Research & Development Day for investors on ...
January 3, 2019
Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China
BUFFALO, N.Y., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
January 3, 2019
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics ...
January 3, 2019
Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals
TEL AVIV, Israel, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing ...
January 3, 2019
OncoCyte Announces Transition to Ion Torrent Next-Generation Sequencing Platform
ALAMEDA, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
January 3, 2019
EDAP TMS SA : John Wayne Cancer Institute First US Medical Center to Acquire EDAP's Breakthrough Focal One® Technology for Prostate Tissue Ablation
LYON, France -- January 3, 2019 - EDAP TMS SA (EDAP) today announced that the John Wayne Cancer Institute (JWCI) at the Providence Saint John's ...
January 3, 2019
Cellectar Biosciences to Present at the Biotech Showcase
FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
January 3, 2019
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
JENA, Germany and NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases ...
January 3, 2019
OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference
NANTES, France, Jan. 03, 2019 (GLOBE NEWSWIRE) --  OSE Immunotherapeutics(ISIN: FR0012127173; Mnémo: OSE), today announced that Alexis Peyroles, CEO, will present an overview of the ...
January 3, 2019
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in ...
January 2, 2019
Acer Therapeutics Announces In-license of Osanetant from Sanofi
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
January 2, 2019
AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer
GARDEN CITY, N.Y. and REHOVOT, Israel, Jan. 02, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
January 2, 2019
BioLineRx to Present at the 2019 Biotech Showcase
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that management will provide a corporate update at the 2019 ...
January 2, 2019
Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement
CRANBURY, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) today announced that it closed on the third tranche (of four) ...
January 2, 2019
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced ...
January 2, 2019
Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
BOSTON and LONDON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
January 2, 2019
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
December 20, 2018
iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures
NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a  global medical technology company providing innovative cancer detection and therapy solutions, today announced ...
December 20, 2018
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
Page 30 of 149